Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study
Tóm tắt
Từ khóa
Tài liệu tham khảo
Chave, 2005, Toxic epidermal necrolysis: current evidence, practical management and future directions, Br J Dermatol, 153, 241, 10.1111/j.1365-2133.2005.06721.x
Sheridan, 2005, Case records of the Massachusetts General Hospital, case 34-2005: a 10-year-old girl with a bullous skin eruption and acute respiratory failure, N Engl J Med, 353, 2057, 10.1056/NEJMcpc059029
Auquier-Dunant, 2002, Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study, Arch Dermatol, 138, 1019, 10.1001/archderm.138.8.1019
Roujeau, 1995, Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis, N Engl J Med, 333, 1600, 10.1056/NEJM199512143332404
Bastuji-Garin, 1993, A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme, Arch Dermatol, 129, 92, 10.1001/archderm.1993.01680220104023
Mockenhaupt, 2002, Cutaneous adverse drug reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis, ACI International, 14, 143
Bastuji-Garin, 2000, SCORTEN: a severity-of-illness score for toxic epidermal necrolysis, J Invest Dermatol, 115, 149, 10.1046/j.1523-1747.2000.00061.x
Guegan, 2006, Performance of SCORTEN during the first five days of hospitalization to predict the prognosis of toxic epidermal necrolysis, J Invest Dermatol, 126, 272, 10.1038/sj.jid.5700068
Renfro, 1989, Drug-induced toxic epidermal necrolysis treated with cyclosporin, Int J Dermatol, 28, 441, 10.1111/j.1365-4362.1989.tb02502.x
Heng, 1991, Efficacy of cyclophosphamide in toxic epidermal necrolysis, clinical and pathophysiologic aspects, J Am Acad Dermatol, 25, 778, 10.1016/S0190-9622(08)80969-3
Arevalo, 2000, Treatment of toxic epidermal necrolysis with cyclosporin A, J Trauma, 48, 473
Halebian, 1986, Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids, Ann Surg, 204, 503, 10.1097/00000658-198611000-00001
Kelemen, 1995, Burn center care for patients with toxic epidermal necrolysis, J Am Coll Surg, 180, 273
Herndon, 1995, Toxic epidermal necrolysis, a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids, J Am Coll Surg, 180, 340
Wolkenstein, 1998, Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis, Lancet, 352, 1586, 10.1016/S0140-6736(98)02197-7
Viard, 1998, Inhibition of toxic epidermal necrolysis by blockage of CD95 with human intravenous immunoglobulin, Science, 282, 490, 10.1126/science.282.5388.490
Stella, 2001, Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience, Dermatology, 203, 45, 10.1159/000051702
Prins, 2003, Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases, Arch Dermatol, 139, 26, 10.1001/archderm.139.1.26
Bachot, 2003, Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis, Arch Dermatol, 139, 33, 10.1001/archderm.139.1.33
Trent, 2003, Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN–the University of Miami experience, Arch Dermatol, 139, 39, 10.1001/archderm.139.1.39
Campione, 2003, High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis, Acta Derm Venereol, 83, 430
Prins, 2003, Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective multicenter study, Dermatology, 207, 96, 10.1159/000070957
Brown, 2004, Toxic epidermal necrolysis: does immunoglobulin make a difference?, J Burn Care Rehabil, 25, 81, 10.1097/01.BCR.0000105096.93526.27
Shortt, 2004, Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis, J Burn Care Rehabil, 25, 246, 10.1097/01.BCR.0000124746.33279.86
Faye, 2005, Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIg): clinical experience to date, Drugs, 65, 2085, 10.2165/00003495-200565150-00002
Bachot, 2003, Intravenous immunoglobulins in the treatment of severe drug eruptions, Curr Opin Allergy Clin Immunol, 3, 269, 10.1097/00130832-200308000-00006
French, 2006, Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: Our current understanding, Int Immunopharmacol, 6, 543, 10.1016/j.intimp.2005.11.012
Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavnick JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risk with emphasis on recently marketed drugs: the EuroSCAR-study. J Invest Dermatol doi:10.1038/sj.jid.5701033. Published online September 6, 2007.
Wolff, 2003, Treatment of toxic epidermal necrolysis: the uncertainty persists but the fog is dispersing, Arch Dermatol, 139, 85, 10.1001/archderm.139.1.85
Roujeau, 1994, Severe adverse cutaneous reactions to drugs, N Engl J Med, 331, 1272, 10.1056/NEJM199411103311906
Nassif, 2004, Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells, J Allergy Clin Immunol, 114, 1209, 10.1016/j.jaci.2004.07.047